Author

Li Zhou

Simcere Pharmaceutical (China)ORCID 0009-0000-5000-6679Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Li Zhou8 papers · Brigham and Women's Hospital

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Chunxia Ao· 1 shared Feng ZhouiD· 1 shared Gang Liu· 1 shared Jiajia LiiD· 1 shared Jing DaiiD· 1 shared Lei JiangiD· 1 shared Liting XueiD· 1 shared Lu LiuiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Chunxia Ao

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintApr 19, 2025

ZMS-6659, a selective Polθ helicase inhibitor, demonstrates anti-tumor activity as monotherapy and synergy effect with PARP inhibitors and topoisomerase inhibitors

Lei Jiang, Jiajia Li, Lu Liu…·Liting Xue

ZMS-6659, a Polθ helicase inhibitor, shows anti-tumor activity as monotherapy and synergizes with PARP inhibitors and topoisomerase inhibitors in HR-deficient and HR-proficient models.

DOI 10.1101/2025.04.19.649634

humanexperimental assay

𝕏 PostBluesky